STOCK TITAN

Immuneering holder Zeskind reports 6.6% stake

Benjamin J. Zeskind reports beneficial ownership of 4,357,807 shares of Immuneering Corporation Class A common stock, representing 6.6% of the class.

Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Benjamin J. Zeskind reports beneficial ownership of 4,357,807 shares of Immuneering Corporation Class A common stock, representing 6.6% of the class. This ownership is calculated as of December 31, 2025, based on 64,569,967 shares outstanding as of November 5, 2025, as disclosed in Immuneering’s Form 10-Q. The position includes 2,312,852 shares held directly, 1,150,028 shares underlying stock options exercisable on or before March 1, 2026, and 894,927 shares held by the Benjamin J. Zeskind 2020 Family Trust, for which his spouse is sole trustee. Zeskind has sole voting and dispositive power over 3,462,880 shares and shared voting and dispositive power over 894,927 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



BENJAMIN J. ZESKIND
Signature:/s/ Benjamin J. Zeskind
Name/Title:Benjamin J. Zeskind
Date:01/22/2026

Keep reading